Funds and ETFs Harrow, Inc.

Equities

HROW

US4158581094

Pharmaceuticals

Market Closed - OTC Markets 04:00:00 2024-04-26 pm EDT 5-day change 1st Jan Change
10.53 USD +5.30% Intraday chart for Harrow, Inc. +0.77% -5.98%

ETFs positioned on Harrow, Inc.

Name Weight AuM 1st Jan change Investor Rating
0.00% 34 M€ +2.14% -
Harrow, Inc. is an eyecare pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the United States market. It provides a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
10.53 USD
Average target price
26.65 USD
Spread / Average Target
+153.09%
Consensus
  1. Stock Market
  2. Equities
  3. HROW Stock
  4. Funds and ETFs Harrow, Inc.